GB201119089D0 - Treatment of musculoskeletal fibroproliferative disorders - Google Patents

Treatment of musculoskeletal fibroproliferative disorders

Info

Publication number
GB201119089D0
GB201119089D0 GBGB1119089.9A GB201119089A GB201119089D0 GB 201119089 D0 GB201119089 D0 GB 201119089D0 GB 201119089 A GB201119089 A GB 201119089A GB 201119089 D0 GB201119089 D0 GB 201119089D0
Authority
GB
United Kingdom
Prior art keywords
treatment
fibroproliferative disorders
musculoskeletal fibroproliferative
musculoskeletal
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1119089.9A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford University Innovation Ltd
Original Assignee
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford University Innovation Ltd filed Critical Oxford University Innovation Ltd
Priority to GBGB1119089.9A priority Critical patent/GB201119089D0/en
Publication of GB201119089D0 publication Critical patent/GB201119089D0/en
Priority to PCT/EP2012/071642 priority patent/WO2013064585A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compositions comprising mechanosensitive ion channel blockers, such as gadolinium, or N-cadherin antagonists or connexin 43 inhibitors enable musculoskeletal fibroproliferative disorders, such as Dupuytren's and other fibromatosis and like disease, characterized by contracture to be slowed, halted or reversed.
GBGB1119089.9A 2011-11-04 2011-11-04 Treatment of musculoskeletal fibroproliferative disorders Ceased GB201119089D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1119089.9A GB201119089D0 (en) 2011-11-04 2011-11-04 Treatment of musculoskeletal fibroproliferative disorders
PCT/EP2012/071642 WO2013064585A1 (en) 2011-11-04 2012-11-01 Treatment of musculoskeletal fibroproliferative disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1119089.9A GB201119089D0 (en) 2011-11-04 2011-11-04 Treatment of musculoskeletal fibroproliferative disorders

Publications (1)

Publication Number Publication Date
GB201119089D0 true GB201119089D0 (en) 2011-12-21

Family

ID=45421293

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1119089.9A Ceased GB201119089D0 (en) 2011-11-04 2011-11-04 Treatment of musculoskeletal fibroproliferative disorders

Country Status (2)

Country Link
GB (1) GB201119089D0 (en)
WO (1) WO2013064585A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104203280A (en) * 2012-03-27 2014-12-10 诺华股份有限公司 Treatment of fibrosis
EP3019017A4 (en) * 2013-07-11 2017-09-27 180 Therapeutics LP Method of treating fibroproliferative disorders including dupuytren ' s disease with one or more specific human matrix metalloproteinase and a tnf antagonist
WO2018226795A1 (en) * 2017-06-06 2018-12-13 The Regents Of The University Of California Humanized anti-n-cadherin antibodies and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3149180B2 (en) * 1989-07-31 2001-03-26 マサチユセツツ・インスチチユート・オブ・テクノロジー Use of calcium antagonists to treat scars
US5589171A (en) 1994-08-22 1996-12-31 Advance Biofactures Of Curacao Treatment of Dupuytren's disease with collagenase
CN1083337C (en) 1996-03-26 2002-04-24 精工爱普生株式会社 Printing device and its control method
US6086872A (en) 1997-03-27 2000-07-11 Advance Biofactures Of Curacao, Nv Amelioration of dupuytren's disease
US6031005A (en) * 1998-08-03 2000-02-29 Easterling; W. Jerry Composition and method for treating Peyronie's disease and related connective tissue disorders
GB0105330D0 (en) 2001-03-02 2001-04-18 Renovo Ltd Genetic testing
GB0306165D0 (en) 2003-03-18 2003-04-23 Delta G Ltd Medical treatment
US20100278821A1 (en) 2006-03-21 2010-11-04 The Regents Of The University Of California N-cadherin: target for cancer diagnosis and therapy
AU2008343841A1 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of inhibitors of connexin43 for treatment of fibrotic conditions
US8703920B2 (en) 2008-11-10 2014-04-22 The Regents Of The University Of California Fully human antibodies against N-cadherin
NZ595564A (en) 2009-03-06 2013-03-28 Kenneth William Gregg Composition for controlling fish feeding behaviour using bacteria derived from a source fish
JP5649589B2 (en) 2009-03-06 2015-01-07 ハロザイム インコーポレイテッド Temperature-sensitive mutant of matrix metalloproteinase 1 and use thereof

Also Published As

Publication number Publication date
WO2013064585A1 (en) 2013-05-10

Similar Documents

Publication Publication Date Title
IL274469A (en) Compositions, uses and methods for treatment of metabolic disorders and diseases
GEP20156372B (en) Pyridazinone compounds and their use as daao inhibitors
GEP201706695B (en) Substituted 4-phenyl-pyridi-nes for the treatment of nk-1 receptor related diseases
PH12015501494A1 (en) Method for producing substituted 5-fluoro-1h-pyrazolopyrimidines
PH12014501967B1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
MX2013001234A (en) Deuterated tandospirone derivatives as 5-ht1a receptor agonists.
MX2016005760A (en) Gsk-3 inhibitors.
IN2015DN03145A (en)
SG10201602670QA (en) Compositions comprising and methods of using inhibitors of sodium-glucose cotransporters 1 and 2
JO3334B1 (en) Oxazolidin-2-one-PyrimidineDerivatives
MX2013012233A (en) Substituted 4-aryl-n-phenyl-1,3,5-triazin-2-amines.
PH12014501195A1 (en) Novel 2h-indazoles as ep2, receptor antagonists
MX2013004759A (en) Oxime compounds as hdl-cholesterol raising agents.
UA111628C2 (en) COMPOSITION FOR PLANT DISEASE AND ITS APPLICATION
EA201391056A1 (en) Heteroaryl compounds as ligands of the 5-HTRECEPTOR
SG10201900541QA (en) Derivatives of xanthone compounds
MX2015008187A (en) Deuterated alk inhibitors.
IT1406864B1 (en) COMPOSITION FOR ACNE TREATMENT
IN2012DN00763A (en)
MX2015015200A (en) "inhibitors of nicotinamide phosphoribosyltransferase, compositions, products and uses thereof".
IN2015DN00085A (en)
GB201119089D0 (en) Treatment of musculoskeletal fibroproliferative disorders
MY162945A (en) Azole derivative
MX2013006670A (en) 2-carboxamide-4-piperazinyl-benzofuran derivative.
EP2575883A4 (en) Treatment of inflammatory disorders

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)